US equities |
MU $1,088.00 ▲+4.06% NVDA $237.47 ▼-0.74% SNDK $1,692.42 ▲+1.92% SPCX $167.60 ▼-2.51% AMD $645.86 ▼-0.55% AAPL $336.67 ▲+0.91% TSLA $377.81 ▼-0.75% META $721.31 ▼-2.38%
FinancialContent

Eledon Pharmaceuticals, Inc. - Common Stock (NQ:ELDN)

2.420 -0.030 (-1.22%)
Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eledon Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
David-Alexandre (‘DA’) Gros, CEO of Eledon Pharmaceuticals Inc. (NASDAQ: ELDN), to Present at NobleCon20
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Enrollment Completed Four Months Ahead of Schedule 
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ELDN Stock Earnings: Eledon Pharma Misses EPS for Q2 2024 ↗
ELDN stock results show that Eledon Pharma missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
80 Participants (Two-thirds of Projected Recruitment) Enrolled 
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues ↗
You don’t want to overlook these three penny stocks filled to the brim with the potential to make huge leaps in their respective markets. 
Via InvestorPlace
News headline image
3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024 ↗
Although the very idea of millionaire-maker penny stocks implies incredibly high risks, if all cylinders fire, these companies could fly. 
Via InvestorPlace
News headline image
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q1 2024 ↗
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence ↗
Eledon Pharmaceuticals' results from islet cell transplant trial for type 1 diabetes, with tegoprubart showing safety and efficacy in kidney transplant patients. Analysts anticipate significant... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023 ↗
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Kidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To Receive ↗
Eledon Pharmaceuticals announces successful use of tegoprubart in kidney xenotransplant. Promising results show its potential to prevent rejection, marking a significant milestone in organ... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >